Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Chief Strategy/Mkt Officer | August 10, 2017 | August 11, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sonoma Pharmaceuticals, Inc.
Report date August 10, 2017 · Filed August 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 3,392 |
Reported balance
After 2017-08-10 transaction · row 1
1 source rowRow 1 · 2017-08-10 · Purchase · Acquired 600 · Balance 3,392 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2017 Filed Aug 11, 2017 16:10 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | PurchaseCommon Stock, $0.0001 par value | 600 | $5.31 | $3,186.00 |
DisclosureSEC source: 0001683168-17-002053 · umshied_f4.xml · nonDerivative · entry 1 Umscheid Marc · CIK 0001690752 · Chief Strategy/Mkt Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,392 Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 16:19 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantRestricted Shares Common Stock, $0.0001 par value per share | 2,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-17-001691 · umscheid_f4.xml · nonDerivative · entry 1 Umscheid Marc · CIK 0001690752 · Chief Strategy/Mkt Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,792 F1 · security: The restricted shares will vest in equal increments of one-third over two years, e.g. one-third vests immediately on the date of the grant, one-third vests on the first anniversary of the date of the grant, or June 29, 2018, and the remaining one-third vests on the second anniversary of the date of the grant, or June 29, 2019. F2 · price: The restricted shares were granted by the Issuer as a performance bonus award pursuant to the FY2017 Bonus Plan, based on the closing price of the Issuer's common stock of $6.94 on June 29, 2017. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:16 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 17,000 | Not disclosed Strike: $7.06 | Not disclosed |
DisclosureSEC source: 0001683168-17-000824 · umsheid_frm4.xml · derivative · entry 1 Umscheid Marc · CIK 0001690752 · Chief Strategy/Mkt Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 17,000 shares Expires 2027-04-03 F2 · price: The stock options were granted in connection with Mr. Umscheid's service as the Issuer's Chief Strategy and Chief Marketing Officer. F1 · derivative.exercise_date: The stock options vest in three years with the first one-third vesting on the first anniversary of the date of the grant, the second one-third vesting on the second anniversary of the date of the grant and the remainder vesting on the third anniversary of the date of the grant. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 16:26 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | PurchaseCommon Stock, par value $0.0001 per share | 750 | $6.82 | $5,115.00 |
DisclosureSEC source: 0001683168-17-000521 · umscheid_f4-030617.xml · nonDerivative · entry 1 Umscheid Marc · CIK 0001690752 · Chief Strategy/Mkt Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 17:25 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 55,000 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001683168-17-000137 · umscheid_frm4.xml · derivative · entry 1 Umscheid Marc · CIK 0001690752 · Chief Strategy/Mkt Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-01-19 F2 · price: The stock options were granted in connection with Mr. Umscheid's service as the Issuer's Chief Strategy and Chief Marketing Officer. F1 · derivative.exercise_date: The stock options vest in three years with the first one-third vesting on the first anniversary of the date of the grant, the second one-third vesting on the second anniversary of the date of the grant and the remainder vesting on the third anniversary of the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.